STAT+: Medicare’s mum on GLP-1s, and Massachusetts sues United
Tuesday, May 2 – We’ve been asking Medicare for weeks about the cost of giving seniors $50 obesity drugs.
Lilly maintains deal streak with $1.2B pact for Hanmi’s GLP-2 candidate
Tuesday, May 2 – Expanding in the metabolic space, Eli Lilly has struck a back-loaded licensing deal with South Korea’s Hanmi Pharm for a mid-stage GLP-2 agonist being trialed for short bowel syndrome.
Telehealth Booms as Demand for GLP-1s Surges and Questions Mount About Safety, Oversight
Tuesday, May 2 – Many telehealth companies have emerged in recent years offering easy access to GLP-1 weight loss drugs as demand has exploded. Meanwhile, researchers and doctors are concerned that some of these online companies aren’t properly screening or monitoring patients. “It gives a black eye to telemedicine,” one researcher said.
Opinion: I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’
Saturday, May 30 – Long term, we don’t know what tiny doses of GLP-1s for cosmetic weight loss can do, writes a weight-loss doctor.
GLP-1 overdoses increase at an alarming rate as weight loss drugs become easier to buy online
Saturday, May 30 – Within 24 hours of injecting the first dose of a weight loss medication she received following a visit with a telehealth doctor, Karleigh McClain was admitted to the hospital, she said
GLP-1s and Chronic Pancreatitis; Hypoglycemia After Bowel Prep; Lower GI Bleeding
Friday, May 29 – (MedPage Today) — A real-world study of chronic pancreatitis found GLP-1 agonists to be associated with less pain medication use and lower risks for pancreatic interventions, including major surgery. (Gastro Hep Advances)
The FDA expanded the…
Health Roundup: GLP-1s, ‘Sweet Spot’ for Sleep, More
Friday, May 29 – Dr. John Torres, NBC News medical contributor joins TODAY with a roundup of the biggest health stories people are talking about from GLP-1s, to sleep health. He breaks down new studies that show GLP-1s may have even more anti-inflammatory benefits other than just weight loss and explains how to find your “sweet spot” in sleep.
CVS Caremark will cover Lilly’s weight loss drug Zepbound again after patient backlash
Friday, May 29 – CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered medications last year, drugmaker Eli Lilly said.
If You’re On Or Have Been On GLP-1 Medication, I Want To Know Your “Why”
Thursday, May 28 – Influencers have had their say and time on the soapbox — let’s hear from “real” people, please.View Entire Post ›
Tirzepatide Superior to Intensified Conventional Care for Early Type 2 Diabetes
WEDNESDAY, May 27, 2026 — Tirzepatide is superior to intensified conventional care (ICC) for adults with early type 2 diabetes (T2D) uncontrolled with metformin, according to a study published online May 26 in the Annals of Internal…